lsa-lsc kol events 2015-16-yr-to-date in numbers€¦ · • total # people opened the research...

SEPTEMBER 2016

KOL EVENTS – 2015-16

YEAR-TO-DATE

CONFIDENTIAL

KOL EVENTS IN REVIEW – TOTAL NUMBERS

Totals: •  Total # of KOL Calls and Dinners: 60

•  Total # of Individual Participants: 687 people

•  Total # of Companies Participating: 530

•  Total # of Countries Participating: 18

•  Total # of US States Participating: 24

•  Total # of Therapeutic Indications Covered: 20

CONFIDENTIAL

KOL EVENTS IN REVIEW – EXAMPLES OF PAST EVENTS

KOL Series on New Data post-ASH Meeting:

•  Total # of Live Participants: 113

•  Total # Replays: 60+ •  Total # of Buy side Companies Participating:

56

KOL Series Investor Dinner on CAR-T/ TCR:

•  24 A-list Buy Side Investors in Attendance •  Total # People opened the research report:

3000+

InVivo Therapeutics KOL Cocktail Reception:

•  Total # of RSVPs: 68

•  Total # Webcast Replays: 500+

Celyad KOL R&D Breakfast:

•  Total # RSVPs: 75


Looking Ahead in 2016: The number and quality of our investor attendance to our KOL events continues to increase. So far this year, we have averaged 170+ on our webcasts and ~40 attendees for our in-person events.

Aurinia KOL Breakfast:



CoLucid KOL Breakfast:



CONFIDENTIAL

KOL EVENTS IN REVIEW – TOP TEN ATTENDEES

Companies (Sell Side): 1.  Jefferies 2.  SunTrust 3.  Ladenburg Thalmann 4.  Piper Jaffray 5.  HC Wainwright 6.  Laidlaw 7.  Cowen & Company 8.  Stifel 9.  Needham 10. Aegis Capital

Companies (Buy Side): 1.  Bernstein 2.  Everpoint Asset Mgmt 3.  Venrock 4.  QVT 5.  RA Capital 6.  George Weiss Assoc. 7.  OrbiMed 8.  VenBio 9.  Deerfield 10. Sio Capital

CONFIDENTIAL

KOL EVENTS IN REVIEW – COMPANIES ATTENDING 12+ KOL EVENTS

1.  Jefferies 2.  SunTrust 3.  Ladenburg Thalmann 4.  Piper Jaffray 5.  HC Wainwright 6.  Laidlaw 7.  Cowen & Co 8.  Stifel 9.  Needham 10. Venrock 11. Aegis Capital 12.  JMP Securities 13. Bernstein 14. Wedbush 15. Everpoint Asset Mgmt 16. BAML 17. QVT

18. RA Capital 19. Chardan Capital 20. Citi 21. George Weiss Assoc. 22. Oppenheimer & Co 23. OrbiMed 24. Rodman & Renshaw 25. VenBio 26. Deerfield

Management 27. RBC Capital Markets 28. Sio Capital 29. Early Harvest Fund 30. Cantor Fitzgerald 31. DAFNA Capital Mgmt 32.  Iguana Healthcare 33.  JP Morgan

34. Leerink Partners 35. Maxim Group 36. Morgan Stanley 37. Wolfswood Partners 38. Barclays 39. Lombard Odier 40. Roth Capital Partners 41. RW Baird 42. William Blair 43. Arrowpoint 44. Baker Brothers 45. BTIG 46. BVF 47. Goldman Sachs 48. Wells Fargo

Buy side

Sell side/ Banking

CONFIDENTIAL

KOL EVENTS IN REVIEW – ATTENDANCE BY INSTITUTION TYPE

44%

40%

2%

5%

6%3%

KOLEventA+endancebyIns3tu3onType

Buyside

Sellside/Banking

Consul9ng

Corporate

VentureCapital

Other

CONFIDENTIAL

KOL EVENTS IN REVIEW – LOCATIONS OF OUR AUDIENCE

94.31%

0.09% 0.80% 3.15% 0.94% 0.66% 0.05%

US SouthAmerica

Canada EU UK Asia Unknown

A+endancebyLoca3on

79%

1%

2%1% 6%

9%

1% 1%

A+endancebyRegion(US)

Tri-State

Mid-Atlan9c

Midwest

Southeast

NewEngland(MA/RI)

California

CO/NV/WA/UT

Texas

CONFIDENTIAL

KOL SERIES IN REVIEW – TOPICS

Neurology/Neuro-surgery20%

Oncology27%

Endocrinology/Cardiology4%

Hematology5%

Infec9ousDiseases11%

OB-GYN/Reproduc9veEndocrinology

6%

Hepatology/Nephrology8%

Rheumatology2%

Otolaryngology5%

Gene9cDisorders/OrphanDiseases

2%

Radiology1%

Dermatology2%

GeneTherapy

5%

PainMedicine2%

A+endancebyTherapeu3cIndica3on

CONFIDENTIAL

KEY OPINION LEADER (KOL) EVENT CASE STUDY: COLUCID PHARMACEUTICALS (CLCD)

•  Event planned to educate investment community in advance of results from SAMURAI Phase 3 pivotal trial of Lasmiditan in migraine treatment, setting the stage for positive momentum following the data

•  KOL: Richard B. Lipton, M.D., of Albert Einstein College of Medicine.

•  30 buy-side investors and sell-side professionals attended the event in-person

•  115 institutional and retail investors, research analysts, bankers, and business development professionals participated in the live webcast or listened to the replay

•  Selected participants: EverPoint, Deerfield, Orbimed, Weiss Multi-Strategy Advisors, PointState, BVF Partners, HBM Partners, Foresite, Sphera, Venrock, General American Investors, Life Sciences Partners (LSP), Ridgeback, Auriga, Iguana Healthcare, Loeb Capital

•  Industry participants on webcast included Novartis’ Global Head of Search & Evaluation, Neurosciences, and Otsuka’s Director of Innovative Indication, Regulatory Global Pharmaceutical Business

•  Analyst reports published by Stifel and Piper Jaffray

•  Stock price up ~58%

•  Daily trading volume up ~73%

LifeSci Hosted a KOL Meeting on Migraine Treatment for CLCD – 6/28/16

CONFIDENTIAL

Stifel and Piper analysts publish reports on KOL event

6

KEY OPINION LEADER (KOL) EVENT CASE STUDY: COLUCID PHARMACEUTICALS (CLCD)

2

Invitations sent out for KOL event

Px: 58%+ Vol: 73%+

1 CLCD Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine Treatment 3

CLCD invites re-distributed

Live KOL event in NY

4

CLCD

5

CONFIDENTIAL

CLCD KOL EVENT APPENDIX SELECT ATTENDEES (LIVE EVENT AND WEBCAST)

Buy Side Industry Sell Side

Aisling Capital Auriga (Montserrat Global Advisers) Bavarian Capital Management Biotechnology Value Fund

DCF Capital Deerfield Management EverPoint Asset Management

Foresite Capital Fountain Healthcare Partners General American Investors HBM Partners

HSMR Advisors Iguana Healthcare Partners Ikarian Capital

Intersouth Partners Kalka Capital LLC Life Science Partners (LSP) Loeb Partners

Morgan Stanley Wealth Management OrbiMed Advisors PointState

Portola Partners Ridgeback Capital Management Sphera Fund TVM Capital

V2M Capital Venrock Weiss Multi-Strategy Advisors

Aegis Capital Corp. Barclays Cantor Fitzgerald Dawson James Securities

Exane FBR&Co. Jefferies

JP Morgan Ladenburg Thalmann & Co. Laidlaw & Co. Leerink Partners

Maxim Group Mizuho Morgan Stanley

Needham & Company Piper Jaffray & Co. Stifel SunTrust Robinson Humphrey

William Blair & Company

Adaptive Biotechnologies AgeneBio, Inc. AMAG Arbor Pharmaceuticals

Avanir Pharmaceuticals Crossject Fortress Biotech

Immunomedics Impax Labs Innoviva Novartis

Otsuka Pharmaceutical Trevena, Inc Zosano Pharma

CONFIDENTIAL

KEY OPINION LEADER (KOL) EVENT CASE STUDY: ACHAOGEN (AKAO)

•  35 buy-side investors and sell-side professionals attended the event in-person ›  Point 72, Hillhouse, Aisling, Ingalls & Snyder ›  Company conducted a full day of 1x1 investor

meetings booked by LIfeSci following the event

•  99 buy-side investors and sell-side professionals participated in the live webcast or listened to the replay ›  Rock Springs, NEA, EverPoint, Bailard, Venrock, Early

Harvest, Omega, Cormorant

•  KOL Event led to price increase from Katherine Xu, Ph.D., of William Blair

LifeSci Hosted a KOL Meeting on Multi-Drug Resistant Infections for AKAO – 7/19/16

CONFIDENTIAL

KEY OPINION LEADER (KOL) EVENT CASE STUDY: ARADIGM PHARMACEUTICALS (ARDM)

•  Lunch at Palace Hotel, NY with live webcast

•  Event planned to educate investment community in advance of ORBIT-3 and ORBIT-4 Phase 3 data release

•  KOLs: David Griffith MD of U. Texas Health Science Center and Gregory Tino MD of Perelman School of Medicine, U Penn.

•  42 buy-side investors and sell-side professionals attended the event in-person ›  Baker Brothers, Point 72, Aisling Capital, Opus Point, First Eagle, Sio etc.

•  80+ buy-side investors and sell-side professionals participated in the live webcast or listened to the replay

•  Industry participants on webcast included Insmed, industry leader in pulmonary disease

•  Daily trading volume approximately 6x higher

LifeSci Hosted a KOL Meeting on Non-CF Bronchiectasis for ARDM – 9/26/16

CONFIDENTIAL

KEY OPINION LEADER (KOL) EVENT CASE STUDY: ARADIGM PHARMACEUTICALS (ARDM)

2 Company announced last patient dosing in ORBIT-3 and ORBIT-4 P3 studies of Pulmaquin in Non-CF Bronchiectasis patients

1


4


Trading volume on day of KOL event ~ 6x avg volume

ARDM

CONFIDENTIAL

ARDM KOL EVENT APPENDIX SELECT ATTENDEES (LIVE EVENT AND WEBCAST)


Akemi Capital Apple Tree Partners Auriga Capital Management AXA Advisors Baker Bros Bishop Capital Management Black Diamond Crown Point Group First Eagle Investment Management Janus Kalka Investment Management, Katz Associates Kearny Venture Partners Kingdon Lazard Asset Management Magid Family Office Nexthera Capital Opus Point Partners Paulson & Co. Inc. Point 72 Asset Management Second Line Capital Sio Capital Management Syncona Partners Triple Gate Capital, LP V2M Capital Valenti Capital Management Water St. Capital Wolfswood Partners X-L Investments

Aegis Capital Corp. Black Diamond Goldman Sachs Houlihan Lokey Ladenburg Thalmann & Co. Nomura Piper Jaffray & Co. RW Baird Stifel

Bayer CURx Pharmaceuticals Daiichi Sankyo Grifols Insmed Nabriva Therapeutics Nektar Therapeutics

CONFIDENTIAL

KEY OPINION LEADER (KOL) EVENT CASE STUDY: AURINIA PHARMACEUTICALS (AUPH)

•  On August 15, 2016, Aurinia announced topline Phase IIb AURA-LV clinical data on Voclosporin in lupus nephritis. Study met its primary endpoint, but stock declined because of news reports / investor concerns about safety and dose response.

•  KOL event held on Sep 30 in NY to discuss full efficacy data (including pre-specified and ad hoc sub-analyses) and comprehensive safety data from AURA-LV with investment community

•  KOLs: David R.W. Jayne, MD, Vasculitis and Lupus Clinic at University of Cambridge, and William Pendergraft III, MD, PhD, UNC School of Medicine

•  35 buy-side investors and sell-side professionals attended the event in-person

›  Baker Brothers, QVT, Nexthera, BVF, Venrock, Redmile, Orbimed, etc.

•  350+ investors and sell-side professionals participated in the live webcast or listened to the replay

•  Stock price increased 32% day of event on 31.7M shares traded (approx 20x normal trading volume)

LifeSci Hosted a KOL Meeting on Lupus Nephritis (LN) for AUPH – 9/30/16

“This KOL event was a great way for Aurinia to reach a wide audience within the investment community. We were happy to see participation from current shareholders as well as prospective investors on our target list. The logistical aspects of the meeting were handled brilliantly by LifeSci.”

-- Mike Martin, COO of Aurinia Pharmaceuticals

CONFIDENTIAL


KOL Event Led to the Publication of 5 Analyst Notes and 12+ News Articles

CONFIDENTIAL


1 Company announces positive topline Phase IIb AURA-LV clinical data in lupus nephritis Stock declines because of news reports / investor concerns about safety and dose response

3 Company provides update on AURA-LV study, addressing investor concerns


4

Trading vol. on day of KOL event: 31.8MM shares (~20x avg volume)

2


AUPH

CONFIDENTIAL

AUPH KOL EVENT APPENDIX – SELECT ATTENDEES (LIVE EVENT AND WEBCAST)


Abingworth Athyrium Capital Management Auriga Capital Management Baker Bros

Basu Capital BVF Early Harvest Fund

DCF Capital Easton Capital Lumira Capital Nexthera Capital

Opus Point Oracle Partners OrbiMed

Pappas Ventures Passaic Capital Management Prunus Capital Management RA Capital

Redmile Renmark Samphire Capital

Torreya Partners Teralys Capital Venrock Wolfswood Partners

Vivo Capital

Aegis Capital BMO Canaccord Genuity Citi

H..C. Wainwright Ladenburg Thalmann & Co. Leerink

Needham Piper Jaffray & Co. RW Baird Stifel

William Blair

EMD Serono Gilead Idera Sandoz

Transition Therapeutics

lsa-lsc kol events 2015-16-yr-to-date in numbers€¦ · • total # people opened the research...

Documents